VRDN vs. FLGT, CSTL, CDNA, PROG, CELC, NVTA, RDNT, FTRE, ARCT, and VREX
Should you be buying Viridian Therapeutics stock or one of its competitors? The main competitors of Viridian Therapeutics include Fulgent Genetics (FLGT), Castle Biosciences (CSTL), CareDx (CDNA), Progenity (PROG), Celcuity (CELC), Invitae (NVTA), RadNet (RDNT), Fortrea (FTRE), Arcturus Therapeutics (ARCT), and Varex Imaging (VREX). These companies are all part of the "medical" sector.
Viridian Therapeutics vs.
Fulgent Genetics (NASDAQ:FLGT) and Viridian Therapeutics (NASDAQ:VRDN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, community ranking, analyst recommendations and institutional ownership.
Fulgent Genetics received 212 more outperform votes than Viridian Therapeutics when rated by MarketBeat users. However, 65.31% of users gave Viridian Therapeutics an outperform vote while only 61.46% of users gave Fulgent Genetics an outperform vote.
In the previous week, Fulgent Genetics had 2 more articles in the media than Viridian Therapeutics. MarketBeat recorded 2 mentions for Fulgent Genetics and 0 mentions for Viridian Therapeutics. Viridian Therapeutics' average media sentiment score of 1.04 beat Fulgent Genetics' score of 0.00 indicating that Fulgent Genetics is being referred to more favorably in the media.
Fulgent Genetics has higher revenue and earnings than Viridian Therapeutics. Fulgent Genetics is trading at a lower price-to-earnings ratio than Viridian Therapeutics, indicating that it is currently the more affordable of the two stocks.
Fulgent Genetics currently has a consensus target price of $42.33, indicating a potential upside of 54.95%. Viridian Therapeutics has a consensus target price of $42.57, indicating a potential upside of 173.95%. Given Fulgent Genetics' stronger consensus rating and higher possible upside, analysts clearly believe Viridian Therapeutics is more favorable than Fulgent Genetics.
46.1% of Fulgent Genetics shares are owned by institutional investors. 31.8% of Fulgent Genetics shares are owned by company insiders. Comparatively, 1.4% of Viridian Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Fulgent Genetics has a net margin of -15.84% compared to Fulgent Genetics' net margin of -13,462.86%. Viridian Therapeutics' return on equity of -3.29% beat Fulgent Genetics' return on equity.
Fulgent Genetics has a beta of 1.52, suggesting that its stock price is 52% more volatile than the S&P 500. Comparatively, Viridian Therapeutics has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500.
Summary
Fulgent Genetics beats Viridian Therapeutics on 12 of the 18 factors compared between the two stocks.
Get Viridian Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VRDN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding VRDN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Viridian Therapeutics Competitors List
Related Companies and Tools